{"filings":[{"id":1636837,"accession_number":"0001493152-26-033173","cik":1517681,"company_name":"Propanc Biopharma, Inc.","ticker":"PPCB","form_type":"8-K","filed_at":"2026-07-14T20:01:28+00:00","items":["5.02","9.01"],"status":"ready","headline":"Propanc Biopharma appoints Carlo Campiciano to Board, replacing retiring director Annie Van Broekhoven","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Annie Van Broekhoven retired from Board effective July 8, 2026.","Carlo Campiciano appointed to fill vacancy; he is a qualified accountant and former CFO of MedAdvisor.","Director agreement provides $45,000 annual cash compensation paid quarterly.","Equity compensation of 0.5% to 4.99% based on milestone achievements.","Campiciano is independent per Nasdaq/NYSE American standards."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":3896014.3888888885,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":104898,"accession_number":"0001493152-26-008196","cik":1517681,"company_name":"Propanc Biopharma, Inc.","ticker":"PPCB","form_type":"8-K","filed_at":"2026-02-26T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"Propanc Biopharma board changes: Kenyon retires, Brandt appointed","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Dr. Julian Kenyon retired from Board on Feb 20, 2026; remains as medical advisor.","Dr. Ralf Brandt appointed to Board same day; 30+ yrs pharma/oncology experience.","Brandt to receive $45,000 annual compensation under Director Agreement.","Brandt has served as CEO of vivoPharm and held exec roles at Novartis and Bionomics."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":3896014.3888888885,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":104897,"accession_number":"0001493152-26-000834","cik":1517681,"company_name":"Propanc Biopharma, Inc.","ticker":"PPCB","form_type":"8-K","filed_at":"2026-01-07T23:59:59+00:00","items":["3.01"],"status":"ready","headline":"Nasdaq notifies Propanc Biopharma of non-compliance with $1.00 minimum bid price rule","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Notice received Dec 31, 2025; bid price below $1.00 for 35 consecutive business days.","Compliance deadline June 30, 2026; must close at $1.00+ for 10 consecutive days.","If not cured, may get additional 180 days with conditions; else delisting.","Delisting could reduce liquidity, limit equity financing, impair employee incentives.","Company evaluating options to regain compliance; no specific plan announced."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":3896014.3888888885,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":121159,"accession_number":"0001493152-25-021567","cik":1517681,"company_name":"Propanc Biopharma, Inc.","ticker":"PPCB","form_type":"8-K","filed_at":"2025-11-10T23:59:59+00:00","items":["3.02","5.03","9.01"],"status":"ready","headline":"Propanc Biopharma closes $1.0M private placement of Series C Preferred Stock to Hexstone Capital","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Hexstone purchased 100 Series C Preferred shares at $10,000 each plus a warrant for up to 9,900 additional shares; total cash $1,000,099.","Series C Preferred convertible into common at the lesser of $5.00 fixed price or 85% of lowest trading price over a specified period.","Board authorized up to 9,900 shares of Series C Preferred via Certificate of Designation filed November 4, 2025.","Securities issued under private placement exemption per Section 4(a)(2) and Regulation D."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":3896014.3888888885,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":121158,"accession_number":"0001493152-25-018054","cik":1517681,"company_name":"Propanc Biopharma, Inc.","ticker":"PPCB","form_type":"8-K","filed_at":"2025-10-14T23:59:59+00:00","items":["1.01","9.01"],"status":"ready","headline":"Propanc Biopharma enters Series C Preferred Stock financing with Hexstone Capital","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Issues 100 shares of Series C Preferred convertible at lesser of $5.00 fixed or 85% of lowest trading price over conversion period.","Warrant issued to purchase up to 9,900 additional Series C shares at $10,000 per warrant share.","Company reserves shares equal to 200% of maximum conversion shares; closing subject to filing Certificate of Designation with Delaware.","Transaction includes Voting Agreement with officers/directors and Registration Rights Agreement for warrant shares."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":3896014.3888888885,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":137803,"accession_number":"0001641172-25-024872","cik":1517681,"company_name":"Propanc Biopharma, Inc.","ticker":"PPCB","form_type":"8-K","filed_at":"2025-08-19T23:59:59+00:00","items":["1.01","5.02","8.01","9.01"],"status":"ready","headline":"Propanc Biopharma prices $4M public offering, uplists to Nasdaq; appoints two independent directors","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Raised $4M gross ($3.34M net) via public offering of 1M shares at $4.00/sh; underwriters have 45-day option for 150K more.","Common stock began trading on Nasdaq Capital Market on Aug 15 under symbol PPCB, uplisted from OTC Pink.","Appointed Joseph Himy and Annie VanBroekhoven as independent directors on Aug 14; serving on audit, compensation, nominating committees.","Issued Representative's warrants to D. Boral Capital for 30,000 shares at $4.00, exercisable from Feb 2026 to Aug 2030."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":3896014.3888888885,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":137802,"accession_number":"0001641172-25-023580","cik":1517681,"company_name":"Propanc Biopharma, Inc.","ticker":"PPCB","form_type":"8-K","filed_at":"2025-08-13T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Propanc Biopharma appoints Jeannine Zimmerman as CFO effective Aug 13, 2025","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Jeannine Zimmerman, age 48, appointed CFO effective August 13, 2025.","She holds a B.S. in accounting from St. Joseph's College; experience includes SEC filings, audit, and SOX 404 testing.","Prior to appointment, CEO James Nathanielsz had served as both CEO and CFO."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.35,"calibrated_materiality_score":0.35,"market_cap_usd":3896014.3888888885,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":137801,"accession_number":"0001641172-25-021560","cik":1517681,"company_name":"Propanc Biopharma, Inc.","ticker":"PPCB","form_type":"8-K","filed_at":"2025-07-30T23:59:59+00:00","items":["1.01","2.03","3.02","9.01"],"status":"ready","headline":"Propanc Biopharma enters $112,350 convertible note at 22% interest with 1800 Diagonal Lending","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["Issued $112,350 convertible promissory note to 1800 Diagonal Lending LLC at a 22% annual interest rate.","Conversion price is 75% of average lowest trading price over 10 days prior to conversion, with 4.99% beneficial ownership cap.","Maturity date April 30, 2026; company can prepay at 120% premium within 90 days, 125% from 91-180 days.","Proceeds from $107,000 purchase price (after $5,350 original issue discount) used for general working capital.","Events of default include failure to pay, failure to issue conversion shares, and loss of OTC listing."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.4,"calibrated_materiality_score":0.4,"market_cap_usd":3896014.3888888885,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":137800,"accession_number":"0001641172-25-020574","cik":1517681,"company_name":"Propanc Biopharma, Inc.","ticker":"PPCB","form_type":"8-K","filed_at":"2025-07-22T23:59:59+00:00","items":["1.01","2.03","3.02","9.01"],"status":"ready","headline":"Propanc Biopharma issues $82,500 promissory note to accredited investor","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["Principal amount $82,500; purchase price $75,000; 10% annual interest.","Maturity date September 15, 2025; proceeds used for general working capital.","Repayment: 100% of principal if repaid by Aug 18, 2025; 120% if after Aug 18 up to Sept 18, 2025.","Note issued under private placement exemption Rule 506/Reg D; no equity securities sold."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":3896014.3888888885,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":155193,"accession_number":"0001641172-25-016719","cik":1517681,"company_name":"Propanc Biopharma, Inc.","ticker":"PPCB","form_type":"8-K","filed_at":"2025-06-27T23:59:59+00:00","items":["1.01","2.03","3.02","9.01"],"status":"ready","headline":"Propanc Biopharma issues $67,860 convertible note with 35% conversion discount to 1800 Diagonal Lending","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["Principal $67,860 for net $58,000; matures Apr 16, 2026; 15% one-time interest.","Conversion at 65% of lowest trading price in prior 10 days (35% discount); dilution risk.","Payments: $39,019.50 on Dec 15, 2025; then $9,754.88 on Jan 15, Feb 15, Mar 15, Apr 15, 2026.","Default triggers immediate acceleration; includes failure to pay, maintain OTC listing, or SEC reporting.","Proceeds for general working capital; note issued under Regulation D, not registered."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":3896014.3888888885,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":155192,"accession_number":"0001641172-25-015642","cik":1517681,"company_name":"Propanc Biopharma, Inc.","ticker":"PPCB","form_type":"8-K","filed_at":"2025-06-18T23:59:59+00:00","items":["1.01","2.03","3.02","9.01"],"status":"ready","headline":"Propanc Biopharma enters $25K convertible note and $13K AUD loan for working capital","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["Issued $25,000 convertible note to Geebis Consulting at 8% interest; maturity June 2026; conversion price $5.00.","Note sold at $22,500 (10% OID); prepayment options with premiums from 110% to 125% within first 180 days.","Received $13,188 AUD loan from board member at 12% interest, maturing June 30, 2025.","Proceeds from both financings will be used for general working capital purposes.","Note is subject to 4.99% beneficial ownership limitation; conversion price adjusts on default."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"market_cap_usd":3896014.3888888885,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":155191,"accession_number":"0001641172-25-013285","cik":1517681,"company_name":"Propanc Biopharma, Inc.","ticker":"PPCB","form_type":"8-K","filed_at":"2025-06-02T23:59:59+00:00","items":["1.01","2.03","3.02","9.01"],"status":"ready","headline":"Propanc Biopharma issues $60,000 promissory note to accredited investor","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["Principal amount $60,000; purchase price $50,000 (implicit $10,000 discount).","Maturity July 15, 2025; interest at 10% per annum.","Repayment at 100% of principal if on/before July 7, 2025; 120% if after through Aug 7, 2025.","Proceeds for general working capital; note issued under Section 4(a)(2) private placement."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.2,"calibrated_materiality_score":0.2,"market_cap_usd":3896014.3888888885,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":155190,"accession_number":"0001641172-25-009121","cik":1517681,"company_name":"Propanc Biopharma, Inc.","ticker":"PPCB","form_type":"8-K","filed_at":"2025-05-08T23:59:59+00:00","items":["1.01","2.03","3.02","9.01"],"status":"ready","headline":"Propanc Biopharma issues $90K promissory note and extends maturity of old note to June 15, 2025","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["Issued $90,000 principal promissory note at 10% interest for $75,000 purchase price; matures June 15, 2025.","Extended maturity of $202,405.19 note with Ionic Ventures to June 15, 2025; no default for prior non-payment.","Proceeds from new note to be used for general working capital.","Note: 100% principal if repaid by June 7, 2025; 120% if repaid by July 7, 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"market_cap_usd":3896014.3888888885,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":155189,"accession_number":"0001641172-25-005511","cik":1517681,"company_name":"Propanc Biopharma, Inc.","ticker":"PPCB","form_type":"8-K","filed_at":"2025-04-21T23:59:59+00:00","items":["1.01","2.03","3.02","9.01"],"status":"ready","headline":"Propanc Biopharma raises ~$180k via convertible notes and board loan; conversion at deep discounts","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["$55k face convertible note issued at $50k (original issue discount) to GS Capital Partners; conversion price $5.00, drops to $2.50 if stock below $4 for 5 days.","$79.2k convertible note issued with 15% one-time interest; conversion at 65% of lowest trading price after default (35% discount).","$63k AUD loan from board member at 12% interest, due June 30, 2025; all proceeds for working capital."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.4,"calibrated_materiality_score":0.4,"market_cap_usd":3896014.3888888885,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":173705,"accession_number":"0001493152-25-010716","cik":1517681,"company_name":"Propanc Biopharma, Inc.","ticker":"PPCB","form_type":"8-K","filed_at":"2025-03-18T23:59:59+00:00","items":["1.01","2.03","3.02","9.01"],"status":"ready","headline":"Propanc Biopharma issues $33K convertible note to GS Capital Partners for working capital","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["Convertible promissory note with $33,000 principal, purchased at $30,000 (original issue discount of $3,000).","Conversion price initially $6.00/share, drops to $3.00 if stock trades below $5.00 for 5 consecutive days.","Note matures Nov 11, 2025, bears 8% interest; prepayment allowed at 110%-125% premiums within first 180 days.","Proceeds from the private placement will be used for general working capital purposes.","Issued to GS Capital Partners, LLC in reliance on Regulation D exemption under Section 4(a)(2)."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.35,"calibrated_materiality_score":0.35,"market_cap_usd":3896014.3888888885,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":173704,"accession_number":"0001493152-25-006126","cik":1517681,"company_name":"Propanc Biopharma, Inc.","ticker":"PPCB","form_type":"8-K","filed_at":"2025-02-12T23:59:59+00:00","items":["1.01","2.03","3.02","9.01"],"status":"ready","headline":"Propanc Biopharma raises $108K in two convertible note financings in Feb 2025","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["$65,000 convertible note (purchase price $56,000) issued Feb 6; 15% flat interest, maturity Nov 30, 2025.","$43,000 convertible note (purchase price $40,000) issued Feb 10; 8% annual interest, maturity Oct 7, 2025.","First note convertible at 35% discount to lowest 10-day trading price; second note at $9/share (or $6 if stock <$8 for 5 days).","Proceeds used for general working capital; notes sold in unregistered offerings under Rule 506(b) and Section 4(a)(2).","Both notes contain events of default including failure to pay, breach of covenants, and conversion share issuance delays."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":3896014.3888888885,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":190670,"accession_number":"0001493152-24-051125","cik":1517681,"company_name":"Propanc Biopharma, Inc.","ticker":"PPCB","form_type":"8-K","filed_at":"2024-12-20T23:59:59+00:00","items":["1.01","2.03","3.02","9.01"],"status":"ready","headline":"Propanc Biopharma raises ~$61k via two convertible notes with dilutive terms","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["Dec 16 note: $22k principal ($20k proceeds), 8% interest, matures June 15, 2025; convertible at $0.0003/share (step-down to $0.0001).","Dec 20 note: $49.2k principal ($41k proceeds), 15% one-time interest, due Oct 15, 2025; conversion at 65% of lowest 10-day trading price.","Proceeds used for general working capital; notes are private placements under Rule 506.","Note terms include 4.99% beneficial ownership cap and prepayment premiums up to 125% face value."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.3,"calibrated_materiality_score":0.3,"market_cap_usd":3896014.3888888885,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":190669,"accession_number":"0001493152-24-049110","cik":1517681,"company_name":"Propanc Biopharma, Inc.","ticker":"PPCB","form_type":"8-K","filed_at":"2024-12-06T23:59:59+00:00","items":["1.01","2.03","9.01"],"status":"ready","headline":"Propanc Biopharma enters $175K AUD loan with Aggro Investments at 12% interest","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["Loan principal $175,000 AUD from Aggro Investments Pty Ltd, due in 4 months or less at company's discretion.","$70,000 AUD due Feb 28, 2024; $105,000 AUD due April 2, 2024; interest 12% per annum monthly.","Additional $15,000 AUD loaned for working capital between Nov 13 and Dec 3, 2024.","Proceeds to repay existing debt, regulatory expenses, and general working capital."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"market_cap_usd":3896014.3888888885,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":207162,"accession_number":"0001493152-24-038462","cik":1517681,"company_name":"Propanc Biopharma, Inc.","ticker":"PPCB","form_type":"8-K","filed_at":"2024-09-27T23:59:59+00:00","items":["1.01","2.03","3.02","9.01"],"status":"ready","headline":"Propanc Biopharma issues $33K convertible note; due March 2025, conversion at $0.0003","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["Issued convertible promissory note with $33,000 principal ($30,000 net) to GS Capital Partners, LLC.","Conversion price set at $0.0003 per share, dropping to $0.0001 if stock trades below that for 5 consecutive days.","Maturity March 25, 2025; 8% annual interest, increasing to 24% on default.","Proceeds used for general working capital; prepayment options with premiums from 110% to 125% in first 180 days.","Note issued under Regulation D as unregistered securities exempt under Section 4(a)(2) of Securities Act."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.2,"calibrated_materiality_score":0.2,"market_cap_usd":3896014.3888888885,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":207161,"accession_number":"0001493152-24-034647","cik":1517681,"company_name":"Propanc Biopharma, Inc.","ticker":"PPCB","form_type":"8-K","filed_at":"2024-08-30T23:59:59+00:00","items":["1.01","2.03","9.01"],"status":"ready","headline":"Propanc Biopharma enters $85K AUD loan from board member for working capital","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["Effective August 26, 2024, company entered loan agreement with a board member for $85,000 AUD.","Loan has no maturity date or interest rate; repayment at company's discretion.","Proceeds used for general working capital."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.2,"calibrated_materiality_score":0.2,"market_cap_usd":3896014.3888888885,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":207160,"accession_number":"0001493152-24-032469","cik":1517681,"company_name":"Propanc Biopharma, Inc.","ticker":"PPCB","form_type":"8-K","filed_at":"2024-08-15T23:59:59+00:00","items":["1.01","2.03","3.02","9.01"],"status":"ready","headline":"Propanc Biopharma issues $33K convertible promissory note to GS Capital at 8% interest","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["Company entered securities purchase agreement with GS Capital Partners on Aug 9, 2024 for $33,000 principal note at $30,000 purchase price.","Note matures Feb 2, 2025, bears 8% interest, convertible at $0.0017/share initially, adjustable to $0.001 if stock trades below $0.0014 for 5 days.","Company can prepay at 110% within 60 days, escalating to 125% after 120 days; no prepayment after 180 days.","Proceeds used for working capital; note issued under Section 4(a)(2) and Rule 506 of Regulation D.","Default events include failure to maintain OTC Markets listing, breach of covenants; interest rises to 24% on default."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"market_cap_usd":3896014.3888888885,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":207159,"accession_number":"0001493152-24-030540","cik":1517681,"company_name":"Propanc Biopharma, Inc.","ticker":"PPCB","form_type":"8-K","filed_at":"2024-08-07T23:59:59+00:00","items":["1.01","2.03","3.02","9.01"],"status":"ready","headline":"Propanc Biopharma enters $150K AUD loan agreement with 12% interest, due Nov 2024","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["Loan of $150,000 AUD effective Aug 1, 2024, with maturity Nov 1, 2024.","Interest rate 12% per annum; prepayable at any time without penalty.","Proceeds will be used for general working capital purposes.","Loan issued under private placement exemption per Section 4(a)(2) and Rule 506."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.35,"calibrated_materiality_score":0.35,"market_cap_usd":3896014.3888888885,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":207158,"accession_number":"0001493152-24-025929","cik":1517681,"company_name":"Propanc Biopharma, Inc.","ticker":"PPCB","form_type":"8-K","filed_at":"2024-07-02T23:59:59+00:00","items":["1.01","2.03","3.02","9.01"],"status":"ready","headline":"Propanc Biopharma issues $33,750 convertible note with 35% discount for working capital","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["Issued convertible promissory note to 104 LLC for gross proceeds of $30,375 after $2,500 legal fee deduction.","Note matures June 20, 2025, bears 10% interest (16% on default), convertible at 65% of lowest closing price over prior 10 days.","Company can prepay at premiums 110-125% of face within first 180 days; no prepayment right after.","Net proceeds used for general working capital; issued under Section 4(a)(2)/Rule 506(b) exemption.","Conversion shares subject to 4.99% beneficial ownership limitation and 500% reserve requirement."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.25,"calibrated_materiality_score":0.25,"market_cap_usd":3896014.3888888885,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":224521,"accession_number":"0001493152-24-024632","cik":1517681,"company_name":"Propanc Biopharma, Inc.","ticker":"PPCB","form_type":"8-K","filed_at":"2024-06-21T23:59:59+00:00","items":["1.01","2.03","3.02","9.01"],"status":"ready","headline":"Propanc Biopharma raises $41K via convertible note with 35% discount conversion","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["Issued $49,200 convertible promissory note to 1800 Diagonal Lending LLC for $41,000, net proceeds for working capital.","Note bears 15% one-time interest, maturity April 15, 2025, with five scheduled payments totaling $56,580.","Conversion price set at 65% of lowest trading price over 10 prior trading days (35% discount) upon event of default.","Investor is accredited; note issued under Section 4(a)(2) and Regulation D exemption."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.25,"calibrated_materiality_score":0.25,"market_cap_usd":3896014.3888888885,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":224515,"accession_number":"0001493152-24-023626","cik":1517681,"company_name":"Propanc Biopharma, Inc.","ticker":"PPCB","form_type":"8-K/A","filed_at":"2024-06-13T23:59:59+00:00","items":["1.01","2.03","3.02","9.01"],"status":"ready","headline":"Propanc Biopharma enters two loan agreements totaling AUD $120,000 at 12% interest","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["First loan of AUD $20,000 on June 3, 2024; 12% annual interest; matures June 3, 2025.","Second loan of AUD $100,000 on June 5, 2024; 12% annual interest; matures June 5, 2025.","Both loans for general working capital; company may prepay without penalty.","Loans issued as unregistered securities under Section 4(a)(2) and Rule 506."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"market_cap_usd":3896014.3888888885,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":224520,"accession_number":"0001493152-24-023525","cik":1517681,"company_name":"Propanc Biopharma, Inc.","ticker":"PPCB","form_type":"8-K","filed_at":"2024-06-12T23:59:59+00:00","items":["1.01","2.03","3.02","9.01"],"status":"ready","headline":"Propanc Biopharma enters loans totaling $120K AUD at 12% interest","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["First loan of $20,000 AUD on June 3, 2024, at 12% annual interest, maturing June 3, 2025.","Second loan of $100,000 AUD on June 5, 2024, at 12% annual interest, maturing June 5, 2025.","Proceeds used for general working capital; prepayment allowed without penalty.","Loans issued under Section 4(a)(2) private placement exemption."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.25,"calibrated_materiality_score":0.25,"market_cap_usd":3896014.3888888885,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":224519,"accession_number":"0001493152-24-022624","cik":1517681,"company_name":"Propanc Biopharma, Inc.","ticker":"PPCB","form_type":"8-K","filed_at":"2024-06-05T23:59:59+00:00","items":["1.01","2.03","3.02","9.01"],"status":"ready","headline":"Propanc Biopharma closes $49,200 convertible note financing with 15% interest, net $41,000","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["Entered securities purchase agreement with 1800 Diagonal Lending LLC for $49,200 convertible note; purchase price $41,000 (includes $8,200 OID).","Note matures March 30, 2025; one-time 15% interest, total payback $56,580 due in five installments starting Nov 30, 2024.","Upon event of default, investor may convert at 65% of lowest trading price in prior 10 days (35% discount).","Proceeds used for general working capital; issuance exempt under Section 4(a)(2) and Rule 506 of Regulation D.","Company has approximately 183.3 million shares of common stock outstanding as of May 22, 2024."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.35,"calibrated_materiality_score":0.35,"market_cap_usd":3896014.3888888885,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":224518,"accession_number":"0001493152-24-020101","cik":1517681,"company_name":"Propanc Biopharma, Inc.","ticker":"PPCB","form_type":"8-K","filed_at":"2024-05-16T23:59:59+00:00","items":["1.01","2.03","9.01"],"status":"ready","headline":"Propanc Biopharma extends $177,980 note maturity to Sept 30, 2024","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["Maturity of 10% OID Promissory Note with Ionic Ventures extended from Nov 15, 2023 to Sept 30, 2024.","Current principal amount $177,980; original principal $132,000.","Parties agree no event of default solely due to late payment of principal and interest.","All other terms of the Note remain in full force and effect."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.3,"calibrated_materiality_score":0.3,"market_cap_usd":3896014.3888888885,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":224517,"accession_number":"0001493152-24-015494","cik":1517681,"company_name":"Propanc Biopharma, Inc.","ticker":"PPCB","form_type":"8-K","filed_at":"2024-04-22T23:59:59+00:00","items":["1.01","2.03","3.02","9.01"],"status":"ready","headline":"Propanc Biopharma issues $27,500 convertible note to GS Capital Partners","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["Entered into securities purchase agreement; note principal $27,500 at $25,000 purchase price (original issue discount).","Note bears 8% interest (24% on default), matures October 12, 2024; conversion price initially $0.0017/share.","Conversion price adjusts to $0.001 if stock trades below $0.0014 for 5 consecutive days; default triggers alternate fixed price.","Company may prepay at 110-125% within 180 days; after 180 days no prepayment right.","Note issued under Regulation D private placement; proceeds for general working capital."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"market_cap_usd":3896014.3888888885,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":224516,"accession_number":"0001493152-24-014213","cik":1517681,"company_name":"Propanc Biopharma, Inc.","ticker":"PPCB","form_type":"8-K","filed_at":"2024-04-10T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Propanc Biopharma updates corporate presentation; no material specifics disclosed in filing","summary_kind":"llm","event_type":"other_material","confidence":"low","bullets":["Filing states company updated its corporate overview and company presentation.","No new financial or operational details provided in the body of the 8-K.","Exhibit 99.1 is referenced but its contents are not summarized; investors must review presentation for details."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.2,"calibrated_materiality_score":0.2,"market_cap_usd":3896014.3888888885,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":243823,"accession_number":"0001493152-24-009536","cik":1517681,"company_name":"Propanc Biopharma, Inc.","ticker":"PPCB","form_type":"8-K","filed_at":"2024-03-11T23:59:59+00:00","items":["1.01","2.03","3.02","9.01"],"status":"ready","headline":"Propanc Biopharma raises $46,875 via convertible note at 35% discount and 8% interest","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["Principal amount $50,000; purchase price $46,875; net proceeds for working capital.","Conversion price = 65% of lowest closing trade price over prior 10 trading days (35% discount).","Interest 8% per annum (16% on default); maturity March 1, 2024 (same as issuance date).","Prepayment rights within 180 days at 110% to 125% premium; no prepayment after 180 days.","Note issued under Regulation D, unregistered; subject to 4.99% beneficial ownership limitation."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":3896014.3888888885,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":261234,"accession_number":"0001493152-23-045035","cik":1517681,"company_name":"Propanc Biopharma, Inc.","ticker":"PPCB","form_type":"8-K","filed_at":"2023-12-15T23:59:59+00:00","items":["1.01","2.03","3.02","9.01"],"status":"ready","headline":"Propanc Biopharma issues $150K convertible note to One44 Capital at 10% interest, 60% conversion discount","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["Principal $150K; purchase price $135K (15% OID); 10% interest; maturity Dec 8, 2024.","Convertible at 60% of lowest trading price over prior 15 days; subject to 4.99% beneficial ownership cap.","Issued under Regulation D private placement; net proceeds for working capital.","Prepayment option: 115% within 60 days, 130% 61-120 days, 140% 121-180 days; none after 180 days."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"market_cap_usd":3896014.3888888885,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":261233,"accession_number":"0001493152-23-044022","cik":1517681,"company_name":"Propanc Biopharma, Inc.","ticker":"PPCB","form_type":"8-K","filed_at":"2023-12-07T23:59:59+00:00","items":["1.01","2.03","3.02","9.01"],"status":"ready","headline":"Propanc Biopharma issues $45K convertible note with 35% discount conversion","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["Principal $45,000; maturity Sept 15, 2024; interest 8% (22% default); issued to 1800 Diagonal Lending LLC.","Conversion price at 35% discount to avg of lowest 3 trading prices over 10 days prior; 4.99% beneficial ownership cap.","Company may prepay within 180 days at escalating premiums: 110% to 129% of principal plus interest.","Proceeds for general working capital; company also pays $5,000 buyer's legal/due diligence fees.","Note issued under Section 4(a)(2)/Reg D private placement exemption."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":3896014.3888888885,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":261232,"accession_number":"0001493152-23-038668","cik":1517681,"company_name":"Propanc Biopharma, Inc.","ticker":"PPCB","form_type":"8-K","filed_at":"2023-10-30T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"Propanc Biopharma closes $40K convertible note with investor","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["Closed sale of $40K convertible promissory note to an investor on Oct 29, 2023.","Note is convertible into common shares at investor's option after 180 days from issuance.","Funds were received and transaction closed on Oct 29; initially disclosed on Oct 26, 2023.","Proceeds likely for general working capital; no other material terms changed from prior disclosure."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.2,"calibrated_materiality_score":0.2,"market_cap_usd":3896014.3888888885,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":261231,"accession_number":"0001493152-23-038400","cik":1517681,"company_name":"Propanc Biopharma, Inc.","ticker":"PPCB","form_type":"8-K","filed_at":"2023-10-26T23:59:59+00:00","items":["1.01","2.03","3.02","9.01"],"status":"ready","headline":"Propanc Biopharma issues $40K convertible note to 1800 Diagonal Lending","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["Principal $40,000, convertible at 65% of lowest three trading prices in prior ten trading days.","Interest 8% per annum (22% on default); maturity October 20, 2024.","Company may prepay at 110%-129% premium within first 180 days; no prepayment after that.","Proceeds used for general working capital; funds not yet received as of filing date.","Conversion subject to 4.99% beneficial ownership limitation; 500% initial share reserve required."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":3896014.3888888885,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":261230,"accession_number":"0001493152-23-037423","cik":1517681,"company_name":"Propanc Biopharma, Inc.","ticker":"PPCB","form_type":"8-K","filed_at":"2023-10-17T23:59:59+00:00","items":["1.01","2.03","3.02","9.01"],"status":"ready","headline":"Propanc Biopharma issues $61K convertible note to GS Capital; conversion at $0.015, adjustable to $0.0075","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["Entered securities purchase agreement with GS Capital Partners, LLC for $61,000 principal convertible note at 8% interest.","Note purchased at $57,500 ($3,500 OID); net proceeds for general working capital.","Conversion price initially $0.015/share, reduced to $0.0075 if stock trades <$0.01 for 5+ consecutive trading days.","Maturity April 12, 2024; prepayment options: 110% within 60 days, scaling to 125% by 180 days.","Events of default include failure to timely issue conversion shares, loss of OTC listing, and non-compliance with SEC reporting."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":3896014.3888888885,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":278486,"accession_number":"0001493152-23-030413","cik":1517681,"company_name":"Propanc Biopharma, Inc.","ticker":"PPCB","form_type":"8-K","filed_at":"2023-08-29T23:59:59+00:00","items":["1.01","2.03","3.02","9.01"],"status":"ready","headline":"Propanc Biopharma raises $72,500 via convertible note with aggressive conversion terms","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["$77,500 convertible note issued to GS Capital Partners; net proceeds $72,500, 8% interest, matures Feb 2024.","Initial conversion price $0.04/share; drops to $0.02 if stock trades below $0.03 for five consecutive days.","Company may prepay at 110%-125% premium within 180 days; after that no prepayment right.","Proceeds for general working capital; note issued under Regulation D, unregistered.","Default triggers 24% interest and potentially lower conversion price based on lowest trading price."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":3896014.3888888885,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":278485,"accession_number":"0001493152-23-029723","cik":1517681,"company_name":"Propanc Biopharma, Inc.","ticker":"PPCB","form_type":"8-K","filed_at":"2023-08-21T23:59:59+00:00","items":["1.01","2.03","3.02","9.01"],"status":"ready","headline":"Propanc Biopharma enters $55K convertible note and $132K promissory note financings","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["Issued $55,000 convertible promissory note to 1800 Diagonal Lending LLC, convertible at 65% of market price after 180 days, 8% interest, matures Aug 16, 2024.","Issued $132,000 face (10% OID) promissory note for $120,000 proceeds, 10% interest, matures Nov 15, 2023; prepayable at 110%-130% premium.","Proceeds from both notes will be used for general working capital; notes issued under Section 4(a)(2) and Rule 506 private placement exemptions.","Convertible note includes prepayment options with escalating premiums (110% to 129% within 180 days) and default triggers 150% acceleration.","Promissory note default interest increases to 18%; Company must maintain corporate existence and cannot sell substantially all assets without consent."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":3896014.3888888885,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":278484,"accession_number":"0001493152-23-027171","cik":1517681,"company_name":"Propanc Biopharma, Inc.","ticker":"PPCB","form_type":"8-K","filed_at":"2023-08-08T23:59:59+00:00","items":["1.01","1.02","2.03","3.02","9.01"],"status":"ready","headline":"Propanc Biopharma issues $45K convertible note at 65% discount; terminates $5M equity line","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["Issued $45,000 convertible promissory note to 1800 Diagonal Lending LLC, convertible at 65% of market price after 180 days.","8% annual interest (22% on default), maturity July 19, 2024; prepayment allowed at premiums up to 129% within 180 days.","Termination of $5,000,000 equity line agreement with an institutional investor on July 25, 2023 due to registration disagreement.","Note issued as unregistered security under Section 4(a)(2) and Regulation D; proceeds for working capital.","Company must maintain share reserve of 500% of conversion shares and avoid becoming shell company without investor consent."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":3896014.3888888885,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":278483,"accession_number":"0001493152-23-025571","cik":1517681,"company_name":"Propanc Biopharma, Inc.","ticker":"PPCB","form_type":"8-K","filed_at":"2023-07-26T23:59:59+00:00","items":["1.01","3.02","9.01"],"status":"ready","headline":"Propanc Biopharma enters $5M equity line with Dutchess Capital at 85% discount","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Up to $5M of common stock sales over 24 months; purchase price 85% of lowest trading price during 7-day pricing period.","Maximum drawdown per notice: the lesser of $200,000 or 200% of 5-day average daily trading value; minimum $5,000 per notice.","Per drawdown, cannot exceed 52.5M shares or cause investor ownership above 4.99% of outstanding shares.","Proceeds used for R&D, clinical study manufacturing, working capital, and general corporate purposes.","Registration statement must be effective before any drawdown; registration rights agreement requires filing within 45 days."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":3896014.3888888885,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":278482,"accession_number":"0001493152-23-024277","cik":1517681,"company_name":"Propanc Biopharma, Inc.","ticker":"PPCB","form_type":"8-K","filed_at":"2023-07-12T23:59:59+00:00","items":["1.01","2.03","3.02","9.01"],"status":"ready","headline":"Propanc Biopharma secures $65K convertible note and AU$230K loan; issues warrant for 15M shares","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["Entered securities purchase agreement with 1800 Diagonal Lending LLC for $65,000 convertible note at 8% interest, convertible at 65% of market price.","Loan agreement with institutional investor for AU$230,000 at 10% interest, 3-year term; issued warrant for 15M shares at $0.01.","Proceeds used to repay ~$143,000 convertible note in default; remaining for working capital.","Convertible note maturity June 29, 2024; prepayment premiums range from 110% to 129%."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":3896014.3888888885,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":296670,"accession_number":"0001493152-23-017322","cik":1517681,"company_name":"Propanc Biopharma, Inc.","ticker":"PPCB","form_type":"8-K","filed_at":"2023-05-15T23:59:59+00:00","items":["1.01","2.03","2.04","3.02","9.01"],"status":"ready","headline":"Propanc Biopharma defaults on $125K convertible note; enters $5M equity facility","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["Entered equity line facility for up to $5M over 36 months; shares sold at 80% of lowest VWAP.","Issued $125K 10% convertible note with $25K OID; $12.5K guaranteed interest; due in 7 monthly payments from March 24, 2023.","Company in default as of March 24, 2023 for failure to make payments and reverse split without consent; discussions to cure.","Warrant holder exercised $150K of Series B warrants; terms extended to March 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":3896014.3888888885,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":296669,"accession_number":"0001493152-23-015643","cik":1517681,"company_name":"Propanc Biopharma, Inc.","ticker":"PPCB","form_type":"8-K","filed_at":"2023-05-05T23:59:59+00:00","items":["3.03","5.03","9.01"],"status":"ready","headline":"Propanc Biopharma effects 1-for-1000 reverse stock split effective May 1, 2023","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Reverse stock split ratio 1-for-1000, effective May 1, 2023.","Common stock assigned new CUSIP number 74346N602.","No fractional shares issued; fractional shares rounded up to nearest whole share.","Outstanding warrants and equity awards adjusted proportionally.","FINRA processing pending for OTC Pink market price adjustment."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":3896014.3888888885,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":317075,"accession_number":"0001493152-23-008082","cik":1517681,"company_name":"Propanc Biopharma, Inc.","ticker":"PPCB","form_type":"8-K","filed_at":"2023-03-17T23:59:59+00:00","items":["5.03","9.01"],"status":"ready","headline":"Propanc Biopharma retires all Series A Preferred Stock; no shares outstanding","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Filed Certificate of Retirement with Delaware to eliminate Series A Preferred Stock from charter.","No shares of Series A Preferred Stock are currently outstanding.","Retired shares become authorized but unissued preferred stock without designation."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"market_cap_usd":3896014.3888888885,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":317074,"accession_number":"0001493152-23-005757","cik":1517681,"company_name":"Propanc Biopharma, Inc.","ticker":"PPCB","form_type":"8-K","filed_at":"2023-02-22T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"Propanc Biopharma retires final convertible note via full conversion to common stock","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["Retired final convertible promissory note dated June 30, 2022, with 1800 Diagonal Lending LLC.","Full payment made on Feb 15, 2023, converting all outstanding principal and interest into common stock.","Zero balance remaining; no further obligations to issue securities to the holder.","No specific financial impact or conversion terms disclosed in the filing."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.4,"market_cap_usd":3896014.3888888885,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":317073,"accession_number":"0001493152-23-005702","cik":1517681,"company_name":"Propanc Biopharma, Inc.","ticker":"PPCB","form_type":"8-K","filed_at":"2023-02-21T23:59:59+00:00","items":["1.01","2.03","3.02","9.01"],"status":"ready","headline":"Propanc Biopharma issues $111,111 convertible note to ONE44 Capital LLC","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["Principal $111,111; net proceeds $100,000 after $11,111 original issue discount.","Interest 10% per annum, payable in common stock; maturity Feb 14, 2024.","Conversion price at 60% of lowest trading price over prior 10 days (50% if DTC chill).","Prepayment allowed within 180 days with premiums of 120%-135% of face amount.","Proceeds used for general working capital; note issued under Section 4(a)(2) exemption."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":3896014.3888888885,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":335321,"accession_number":"0001493152-22-030113","cik":1517681,"company_name":"Propanc Biopharma, Inc.","ticker":"PPCB","form_type":"8-K","filed_at":"2022-11-01T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"Propanc Biopharma enters amended employment agreement with CEO James Nathanielsz","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["New base salary of $600,000 AUD per annum, plus salary sacrifice for tuition up to $200,000 AUD.","Annual discretionary bonus reduced to up to 100% of base salary (from 200% previously).","Term of 3 years from July 1, 2022, with automatic yearly renewal unless terminated.","Severance: one year's base salary upon termination without cause or company non-renewal; only accrued amounts if executive non-renewal.","Includes one-year non-compete and indemnification provisions."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":3896014.3888888885,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":335320,"accession_number":"0001493152-22-028230","cik":1517681,"company_name":"Propanc Biopharma, Inc.","ticker":"PPCB","form_type":"8-K","filed_at":"2022-10-12T23:59:59+00:00","items":["1.01","2.03","3.02","9.01"],"status":"ready","headline":"Propanc Biopharma issues $53,750 convertible note to Red Road with 35% discount conversion","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["Principal $53,750, net proceeds $50,000 after $3,750 fees; maturity Oct 6, 2023; 8% interest.","Conversion price set at 65% of average lowest 3 trading prices in prior 10 days (35% discount).","Prepayment premiums range from 110% to 129% of face amount; conversion begins 180 days after issuance.","Default includes failure to deliver shares, OTC delisting, or financial restatement; default amount 150%.","Note sold in private placement under Section 4(a)(2) and Regulation D; proceeds for working capital."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":3896014.3888888885,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":352756,"accession_number":"0001493152-22-026871","cik":1517681,"company_name":"Propanc Biopharma, Inc.","ticker":"PPCB","form_type":"8-K","filed_at":"2022-09-27T23:59:59+00:00","items":["1.01","2.03","3.02","9.01"],"status":"ready","headline":"Propanc Biopharma issues $71,500 convertible note to GS Capital","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["Principal $71,500 with $4,000 OID; net proceeds $67,500 for general working capital.","Note bears 8% interest; convertible at $0.002/share (fixed) or $0.0009 if stock below $0.0014 for 5 days.","Maturity March 21, 2023; prepayment premiums of 110%-130% depending on timing.","Default conversion price at 65% of lowest trading price over 10 days; default interest 24% per annum.","GS Capital paid $2,500 legal fees; conversion limited to 4.99% beneficial ownership."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":3896014.3888888885,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":352755,"accession_number":"0001493152-22-023445","cik":1517681,"company_name":"Propanc Biopharma, Inc.","ticker":"PPCB","form_type":"8-K","filed_at":"2022-08-18T23:59:59+00:00","items":["1.01","2.03","3.02","9.01"],"status":"ready","headline":"Propanc Biopharma raises $203K via convertible notes with dilutive conversion terms","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["Entered convertible note agreements with GS Capital ($93K principal, net $88K after $5K OID) and ONE44 ($110K principal, net $100K after $10K OID).","Notes bear interest at 8% (GS) and 10% (ONE44), mature in one year (Aug 2023).","Conversion price for GS note fixed at $0.0028/share, dropping to $0.0013 if stock trades under $0.002 for 5 days; ONE44 at 65% of lowest bid.","Prepayment premiums range from 110%-130% (GS) and 120%-135% (ONE44) of face value plus interest, within 180 days.","Proceeds used for general working capital; notes are convertible into common stock with 4.99% beneficial ownership cap."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":3896014.3888888885,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null}],"next_cursor":"2022-08-18T23:59:59+00:00|352755"}